HER2 Support Group Forums - View Single Post - (PARP inhibitors) Experimental cancer drugs cut tumors off from repair tools

Rich66 · 09-18-2009, 09:00 AM

http://www.sidewaysnews.com/science-...s#comment-1089

PARP inhibitors 'can treat many cancers'
A twice-a-day pill designed to treat breast cancer may be able to tackle other forms of the disease, scientists have discovered.
PARP inhibitors have previously shown promise for treating cancers associated with a BRCA gene mutation, but research from Breakthrough Breast Cancer has found that they may useful for fighting other forms of the disease linked to a faulty PTEN gene.
Faults in this gene are thought to be linked to 30-80% of all breast, prostate, skin, womb and colon cancer cases.
The research found that tumours with a faulty PTEN gene were 25-times more sensitive to the drug than those with a normal copy of the gene.
Professor Alan Ashworth, director of the Breakthrough Breast Cancer Research Centre at the Institute of Cancer Research, called the results "exciting".
"PARP inhibitors are potentially a powerful targeted treatment with few side effects which may help a broad range of cancer patients," he added.
There are more than 200 different types of cancer, but four of them – breast, lung, bowel and prostate – account for over half of all new cases.

http://www.nursinginpractice.com/def...ticle.id=18476
Breakthrough in cancer drug study

Wednesday 16th September 2009A new type of drug could be used to treat thousands of cancer patients after experts found it can be used on different types of the disease.

The research, published in the EMBO Molecular Medicine journal, concludes that the drug - known as a PARP inhibitor - is showing "positive signs" in the treatment of breast and ovarian cancer, caused by the faulty BRCA gene.

Scientists now believe the drug could also kill cancers caused by the faulty PTEN gene, including prostate, skin (melanoma), womb and colon cancers. Research shows that the cancer cells are 25 times more sensitive to PARP inhibitors than cells with a normal PTEN gene.

Professor Alan Ashworth, director of the Breakthrough Breast Cancer Research Centre at the Institute of Cancer Research, hailed the results of the study as "exciting".

He said: "These results are exciting because they show that PARP inhibitors are potentially a powerful targeted treatment with few side-effects which may help a broad range of cancer patients."

Prof Ashworth added that tests need to be carried out on a "much larger group of patients with PTEN-related tumours".

09-18-2009, 09:00 AM	#2
Rich66 Senior Member Join Date: Feb 2008 Location: South East Wisconsin Posts: 3,431	Re: (PARP inhibitors) Experimental cancer drugs cut tumors off from repair tools http://www.sidewaysnews.com/science-...s#comment-1089 PARP inhibitors 'can treat many cancers' A twice-a-day pill designed to treat breast cancer may be able to tackle other forms of the disease, scientists have discovered. PARP inhibitors have previously shown promise for treating cancers associated with a BRCA gene mutation, but research from Breakthrough Breast Cancer has found that they may useful for fighting other forms of the disease linked to a faulty PTEN gene. Faults in this gene are thought to be linked to 30-80% of all breast, prostate, skin, womb and colon cancer cases. The research found that tumours with a faulty PTEN gene were 25-times more sensitive to the drug than those with a normal copy of the gene. Professor Alan Ashworth, director of the Breakthrough Breast Cancer Research Centre at the Institute of Cancer Research, called the results "exciting". "PARP inhibitors are potentially a powerful targeted treatment with few side effects which may help a broad range of cancer patients," he added. There are more than 200 different types of cancer, but four of them – breast, lung, bowel and prostate – account for over half of all new cases. http://www.nursinginpractice.com/def...ticle.id=18476 Breakthrough in cancer drug study Wednesday 16th September 2009A new type of drug could be used to treat thousands of cancer patients after experts found it can be used on different types of the disease. The research, published in the EMBO Molecular Medicine journal, concludes that the drug - known as a PARP inhibitor - is showing "positive signs" in the treatment of breast and ovarian cancer, caused by the faulty BRCA gene. Scientists now believe the drug could also kill cancers caused by the faulty PTEN gene, including prostate, skin (melanoma), womb and colon cancers. Research shows that the cancer cells are 25 times more sensitive to PARP inhibitors than cells with a normal PTEN gene. Professor Alan Ashworth, director of the Breakthrough Breast Cancer Research Centre at the Institute of Cancer Research, hailed the results of the study as "exciting". He said: "These results are exciting because they show that PARP inhibitors are potentially a powerful targeted treatment with few side-effects which may help a broad range of cancer patients." Prof Ashworth added that tests need to be carried out on a "much larger group of patients with PTEN-related tumours".